Evidence map›Paper›PMID 38049332›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2023

[Efficacy and safety analysis of the zanubrutinib-based bridging regimen in chimeric antigen receptor T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma].

Y Lu, H Liu, S G Ye, L L Zhou, X Luo, X Y Dang, X G Yuan, W B Qian, A B Liang, P Li

Open access · greenAbstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Observational
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Y LuDepartment of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China.
H LiuDepartment of Hematology, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, China.
S G YeDepartment of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China.
L L ZhouDepartment of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China.
X LuoDepartment of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China.
X Y DangDepartment of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China.
X G YuanDepartment of Hematology, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, China.
W B QianDepartment of Hematology, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, China.
A B LiangDepartment of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China.
P LiDepartment of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China.
Tongji University · CNSecond Affiliated Hospital of Zhejiang University · CN

Funding

National Key R&D Plan Project of the Ministry of Science and Technology 2021YFA1100800National Natural Science Foundation of China 81830004, 82070168, 82170219
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Lymphoma, Large B-Cell, DiffuseReceptors, Chimeric AntigenAntigens, CD19Cell- and Tissue-Based TherapyHumansImmunotherapy, AdoptiveMiddle AgedNeurotoxicity SyndromesPiperidinesPyrazolesPyrimidinesRetrospective StudiesAntigens, CD19cell-associated neurotoxicityPiperidinesPyrazolesPyrimidinesReceptors, Chimeric AntigenzanubrutinibBridging treatmentChimeric antigen receptor T-cellsRelapsed or refractory diffuse large B-cell lymphomaZanubrutinib

Identifiers

PMID38049332
PMCPMC10694070
OpenAlexW4389346257

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.